2026 · 3rd Quarter (July 1 - Sep 30)
Filed by ORCHARD THERAPEUTICS NORTH AMERICA.
Open official filingSource-reported fields
Expense method: A
Literal source text
FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including Appropriations and Accelerating Implementation and Providing Resources for States to Implement for Metachromatic Leukodystrophy (MLD) H.R. 10571: Surge to Save Newborns Act
Literal federal measure citations: H.R. 10571
S.1637/H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act CMS Policies to Support Expedited Implementation of Accelerating Kids' Access to Care Act (AKATCA) and States' Awareness of VBAs
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
